Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$133.87
+0.6%
$130.09
$99.71
$141.23
$232.91B0.746.13 million shs4.92 million shs
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$167.38
+1.4%
$212.37
$163.33
$251.99
$48.06B0.311.84 million shs3.40 million shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$104.81
+0.7%
$98.71
$71.88
$107.17
$155.02B0.686.33 million shs4.39 million shs
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$75.01
+0.1%
$71.30
$58.93
$95.25
$44.10B1.125.01 million shs2.42 million shs
Medtronic plc stock logo
MDT
Medtronic
$83.12
+1.0%
$87.34
$75.96
$96.25
$106.60B0.816.70 million shs7.44 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.55%+2.07%+7.06%+0.90%+26.15%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-1.10%-19.96%-20.62%-32.62%-30.21%
Boston Scientific Co. stock logo
BSX
Boston Scientific
-0.01%+1.49%+16.09%-0.70%+43.65%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
-0.30%-1.76%+8.00%+3.95%-11.93%
Medtronic plc stock logo
MDT
Medtronic
-1.36%-2.86%-0.75%-10.24%+0.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.8915 of 5 stars
2.44.04.24.53.42.52.5
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9281 of 5 stars
4.23.03.34.03.03.31.3
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.0838 of 5 stars
2.53.00.04.23.52.51.3
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
4.6136 of 5 stars
2.25.00.04.04.02.52.5
Medtronic plc stock logo
MDT
Medtronic
4.4795 of 5 stars
3.23.03.34.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.84
Moderate Buy$142.596.51% Upside
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.45
Hold$231.4438.27% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
3.04
Buy$114.529.26% Upside
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
2.42
Hold$79.455.92% Upside
Medtronic plc stock logo
MDT
Medtronic
2.44
Hold$96.1415.67% Upside

Current Analyst Ratings Breakdown

Latest EW, BDX, BSX, MDT, and ABT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$280.00 ➝ $196.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$280.00 ➝ $224.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$260.00 ➝ $185.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$192.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/1/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight
5/1/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$190.00
5/1/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/25/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$118.00 ➝ $125.00
4/25/2025
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$71.00 ➝ $75.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$113.00 ➝ $115.00
(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$42.34B5.50$5.77 per share23.22$22.36 per share5.99
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.87B2.30$15.56 per share10.76$89.57 per share1.87
Boston Scientific Co. stock logo
BSX
Boston Scientific
$17.55B8.83$3.63 per share28.86$14.91 per share7.03
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$5.25B8.39$2.77 per share27.04$11.08 per share6.77
Medtronic plc stock logo
MDT
Medtronic
$33.20B3.21$6.81 per share12.21$38.69 per share2.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.5023.362.5231.95%20.74%11.19%7/17/2025 (Estimated)
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2427.8010.701.638.47%15.74%7.29%N/A
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.85B$1.3783.8532.452.7911.07%17.80%9.85%7/23/2025 (Estimated)
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$4.17B$7.0010.7627.284.8272.93%19.40%14.37%7/23/2025 (Estimated)
Medtronic plc stock logo
MDT
Medtronic
$3.68B$3.2925.2614.262.2212.83%14.07%7.70%5/21/2025 (Estimated)

Latest EW, BDX, BSX, MDT, and ABT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2025
Medtronic plc stock logo
MDT
Medtronic
$1.58N/AN/AN/A$8.81 billionN/A
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
4/23/2025Q1 2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
4/23/2025Q1 2025
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$0.60$0.64+$0.04$0.61$1.40 billion$1.41 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
2/18/2025Q3 2025
Medtronic plc stock logo
MDT
Medtronic
$1.36$1.39+$0.03$1.01$8.33 billion$8.29 billion
2/11/2025Q4 2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$0.55$0.59+$0.04$0.65$1.36 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.76%+7.17%30.61%54 Years
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.49%+5.00%79.39%53 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.803.37%+4.14%85.11%48 Years

Latest EW, BDX, BSX, MDT, and ABT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
2/21/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.75%4/15/20254/15/20255/15/2025
3/6/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703%3/28/20253/28/20254/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.14
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.13
0.63
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.41
1.08
1.02
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
0.06
3.46
2.89
Medtronic plc stock logo
MDT
Medtronic
0.48
1.90
1.39

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
79.46%
Medtronic plc stock logo
MDT
Medtronic
82.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.74 billion1.73 billionOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
77,000287.14 million286.10 millionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
45,0001.48 billion1.47 billionOptionable
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
17,300587.87 million582.19 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable

Recent News About These Companies

Medtronic seeks to bring the next generation into medtech
Medtronic plc (NYSE:MDT) Receives $96.14 Average PT from Analysts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$133.87 +0.81 (+0.61%)
Closing price 03:59 PM Eastern
Extended Trading
$132.18 -1.69 (-1.26%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$167.38 +2.23 (+1.35%)
Closing price 03:59 PM Eastern
Extended Trading
$166.15 -1.23 (-0.73%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$104.81 +0.69 (+0.66%)
Closing price 03:59 PM Eastern
Extended Trading
$104.53 -0.28 (-0.27%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Edwards Lifesciences stock logo

Edwards Lifesciences NYSE:EW

$75.01 +0.09 (+0.12%)
Closing price 03:59 PM Eastern
Extended Trading
$74.25 -0.76 (-1.02%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Medtronic stock logo

Medtronic NYSE:MDT

$83.12 +0.80 (+0.97%)
Closing price 03:59 PM Eastern
Extended Trading
$83.30 +0.18 (+0.22%)
As of 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.